Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Oriola Q1 2026: product segment drives growth, services and Kronans Apotek weigh on results

Oriola reports Q1 2026 revenue up 10.7% (excluding the divested Swedish dose-dispensing business) and a slightly higher adjusted EBITDA of €7.7m. The product segment grew 10% to €15.4m and raised its adjusted EBITDA margin to 13.9%, while the services segment faced margin pressure despite revenue growth. Burdens included losses from the joint venture Kronans Apotek (at-equity effect of €2.3m) and increased investments in ERP and automation; free cash flow turned to -€20.9m. Oriola confirms its 2026 outlook, targeting a higher adjusted EBITDA versus 2025 and focusing on operational efficiency and medium-term transformation measures. » More on de.investing.com
Oriola posts strong sales growth in 2025, weighed down by high transformation costs

Oriola increased net sales in 2025 by 14% to EUR 1,906 million and improved its trading margin and adjusted EBITDA to EUR 35.1 million, but recorded a net loss of EUR 27.2 million. Major burdens were ERP implementation costs of EUR 9.6 million, impairments of EUR 5.7 million and losses from the Kronans Apotek joint venture of EUR 22.8 million. Free cash flow and the balance sheet improved markedly (free cash flow EUR 58.4 million; net cash EUR 82.1 million) and the company plans a highly automated distribution centre in Järvenpää (EUR 110–120 million). For 2026 Oriola expects rising adjusted EBITDA; the board proposes a dividend of EUR 0.03 per share. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Oriola Corp Class B has already paid €0.03 in dividends. The last payout was in April.

Financials

In the last quarter, Oriola Corp Class B had revenue of €51.8m and net profit of -€1.3m

(EUR)	June 2026	YoY
Revenue	51.8m	89.84%
Gross profit	400k	97.22%
Net profit	-1.3m	76.79%
EBITDA	3.8m	137.50%

Fundamentals

Metric	Value
Market capitalization	€136.4m
Number of shares	181.38m
52-week high/low	€1.53 - €0.73
Dividend yield	3.95%
Dividends TTM	€0.03
Beta	0.48
P/E ratio	-7.12
PEG ratio	-0.15
P/B ratio	1.58
P/S ratio	0.13

Company profile

Oriola Oyj provides healthcare and wellbeing products in Sweden, Finland, and internationally. The company offers over the counter (OTC) pharmaceutical and traded goods, vitamins, dietary supplements, cosmetics, skincare products, sports drinks, and wound care products. It also provides logistics, advisory, sales and marketing, and expert services for pharmaceutical companies, pharmacies, hospital pharmacies, veterinaries, as well as the grocery trade shops. In addition, the company offers pharmaceutical staffing and dose dispensing services for public and private healthcare operators, pharmacies, groceries, veterinarians, and retailers. As of December 31, 2021, it operated 319 pharmacies in Sweden, as well as operates online pharmacies. The company was formerly known as Oriola-KD Oyj and changed its name to Oriola Oyj in April 2017. Oriola Oyj is headquartered in Espoo, Finland.